Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Candel Therapeutics, Inc. - Common Stock (NQ: CADL )

7.690 -0.310 (-3.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry 
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small... 
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Upcoming Investor Conference Participation for November
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.